Foundayo vs. Wegovy® Pill: How the Two Oral GLP-1 Medications Compare

What Are Foundayo and the Wegovy® Pill?

When it comes to Foundayo vs the Wegovy® pill, both are FDA-approved GLP-1 receptor agonists taken once daily as a pill, indicated for weight management in adults with obesity (BMI  ≥30) or overweight (BMI  ≥27) with at least one weight-related condition, such as high blood pressure or high cholesterol. They’re typically used alongside a reduced-calorie diet and increased physical activity.

But just because they’re both oral pills approved for similar circumstances, it doesn’t mean they’re the same thing. Foundayo and the Wegovy® pill contain different active ingredients. Foundayo contains orforglipron, and the Wegovy® pill contains semaglutide (the same active ingredient found in Wegovy® and Ozempic® injections). In other words, the comparison of orforglipron vs semaglutide is where these two drugs significantly differ.

They were also approved at different times: the Wegovy® pill (oral semaglutide 25 mg) was granted FDA approval in December 2025, making it the first oral GLP-1 approved for weight loss. Meanwhile, Foundayo (orforglipron) received FDA approval in April 2026 as the first small-molecule oral GLP-1 receptor agonist. 

‍

How Each Drug Works: Peptide vs. Small Molecule

Semaglutide, the active ingredient in the Wegovy® pill, is a peptide. The catch is that these peptides are large, fragile molecules. Stomach acid and digestive enzymes can easily break them down before they’re absorbed. In turn, oral semaglutide has to be taken on an empty stomach with no more than 4 oz (120 mL) of plain water, followed by a 30-minute wait before eating, drinking anything else, or taking other medications.

In contrast, orforglipron, the active ingredient in Foundayo, is a small molecule (a chemically synthesized compound). Since it’s more stable in the digestive environment, it doesn’t need a fasting window or water limits. It can be taken at any time of day, with or without food.

In many ways, you can think of semaglutide as a delicate biological key that only turns in a clean lock (an empty stomach). On the other hand, orforglipron is a sturdier key that fits the same lock regardless of the conditions. 

And both keys open the same door, which is how GLP-1 medications work. Once absorbed, they activate GLP-1 receptors, mimicking the effects of the GLP-1 hormone, which slows how quickly food leaves your stomach, suppresses appetite signals in the brain, and supports blood sugar regulation. 

Both medications, Foundayo and the Wegovy® pill, are prescription-only and require evaluation by a licensed provider before starting.

‍

Dosing and Administration: What Your Daily Routine Looks Like

Since these two medications contain different active ingredients, your daily routine might look a little different depending on which (if any) your provider prescribes. With both pills, your provider also sets and adjusts the dose. Usually, the doses are titrated (gradually increased), which may help reduce common side effects. Check out the sections below to gain a better understanding of what each involves.

‍

Wegovy® Pill (Oral Semaglutide) Dosing Routine

The 30-minute fasting window required by the Wegovy® pill may be inconvenient for individuals who take morning medications, drink coffee immediately upon waking, or have early morning schedules. 

With that in mind, here’s what a typically Wegovy® pill schedule looks like and involves:

• Taken once daily by mouth, first thing in the morning.
• Must be taken on an empty stomach, at least 30 minutes before your first food, any drink other than water, or other oral medications.
• Taken with no more than 4 oz (120 mL) of plain water only (not coffee, juice, or anything else).
• Typically starts at 1.5 mg, then is increased roughly every four weeks to 4 mg, 9 mg, and a maintenance dose of 25 mg, as directed by your provider.
• Tablets are swallowed whole (not crushed, split, or chewed).

‍

Foundayo (Orforglipron) Dosing Routine

Foundayo, when compared to the Wegovy® pill, may offer more flexible dosing schedules, which may be advantageous for individuals with complex morning routines or who take multiple medications. Here’s what it often involves:

• Taken once daily by mouth, at any time of day.
• Can be taken with or without food; there’s no fasting window and no water restrictions.
• Typically starts at 0.8 mg daily, then increases at least every 30 days to 2.5 mg and 5.5 mg, with optional further increases to 9 mg, 14.5 mg, or a maximum of 17.2 mg based on how you respond and tolerate it. Any increase is always provider-led.
• Tablets are swallowed whole.

‍

Clinical Results: How Much Weight Loss Can You Expect?

Both GLP-1 pills have reported weight loss in clinical trials, but the studies used different doses, durations, and patient groups.

For the Wegovy® pill (oral semaglutide), approval was based largely on the 64-week OASIS 4 trial. Researchers reported that adults taking oral semaglutide 25 mg experienced mean weight reductions of about 17% among participants who remained on treatment and about 14% in the overall study population, compared with roughly 2-3% on placebo. Notably, about one in three participants who stayed on treatment lost 20% or more of their body weight.

For Foundayo (orforglipron), the 72-week ATTAIN-1 trial reported average weight reductions ranging from about 7.5% at lower doses to around 11-12% at the highest dose.

The trials differed in length, dose, and design, which makes direct comparison difficult. At the same time, these medications are meant to work alongside a reduced-calorie diet and regular exercise, not as standalone solutions. A licensed healthcare provider can determine what’s best for you and help set realistic expectations based on your individual health profile; individual results may vary.

‍

Side Effects: What to Expect From Each Medication

GLP-1 side effects commonly include gastrointestinal concerns, and unfortunately, both of these pills are no exception. The good news is that any side effects tend to be most noticeable during dose escalation and often ease as your body adjusts.

‍

Foundayo (Orforglipron) Side Effects

The most common side effects reported in Foundayo’s ATTAIN-1 trial included:

• Nausea (roughly 29-36%)
• Constipation
• Diarrhea
• Vomiting
• Indigestion
• Stomach (abdominal) pain
• Headache
• Bloating
• Fatigue
• Belching
• Heartburn (GERD)
• Hair loss

‍

Wegovy® Pill (Oral Semaglutide) Side Effects

The most common side effects reported in the Wegovy® pill’s OASIS 4 trial included:

• Nausea (about 47%)
• Vomiting (about 31%)
• Diarrhea
• Constipation
• Stomach (abdominal) pain
• Headache
• Fatigue

While nausea rates appear higher with oral semaglutide than with orforglipron in the available trial data, cross-trial comparisons should be made cautiously. As noted above, duration and doses varied across clinical trials.

‍

Shared Serious Warnings

Both medications carry the same serious warnings, which a licensed healthcare provider will review with you before prescribing:

• A possible risk of thyroid C-cell tumors (based on animal studies; both carry a boxed warning)
• Pancreatitis
• Gallbladder problems
• Kidney damage
• Low blood sugar (particularly if you also take insulin or a sulfonylurea)
• Serious allergic reactions
• Diabetic retinopathy complications (in individuals with type 2 diabetes)
• Lung complications during general anesthesia or deep sedation

Before starting either medication, discuss your full medical history, current medications, and any prior history of thyroid cancer or pancreatitis with a licensed provider. From there, they can determine what’s best for you.

‍

Who May Be a Better Fit for Each Medication?

Wondering about Wegovy® pill vs Foundayo for your own situation? The following is meant to help you have a more informed conversation with your provider—not to replace one. Both medications require a prescription from a licensed provider who has carefully evaluated your individual health situation.

‍

You May Be a Better Fit for Foundayo If…

• Your morning routine makes a 30-minute fasting window difficult, such as you take other oral medications first thing, drink coffee the moment you wake up, or start work early.
• You want maximum flexibility in when and how you take your medication.
• You’re new to GLP-1 therapy and prefer a dosing routine with fewer requirements.
• Your provider determines that orforglipron suits your health profile.

‍

You May Be a Better Fit for the Wegovy® Pill If…

• You’re already familiar with semaglutide; for example, you’ve used injectable Ozempic® or Wegovy® and want to move to an oral option.
• You’re comfortable with a structured morning routine, and the fasting window feels manageable.
• Your provider has determined that semaglutide is the preferred active ingredient based on your history or prior treatment response.
• You have established cardiovascular disease and obesity or overweight; the Wegovy® pill also carries an approved indication for reducing the risk of major cardiovascular events in eligible adults. 

Both medications have BMI-based eligibility criteria, so if you’re unsure whether you qualify, filling out a BMI calculator may help you see better where you stand before a consultation.

At the end of the day, neither medication is right for everyone. Both require a prescription and a provider evaluation. Your BMI, medical history, other medications, and weight-loss goals all influence which option (if any) is appropriate for you.

‍

Cost and Access: What to Know Before You Start

Both Foundayo and the Wegovy® pill are brand-name, FDA-approved drugs, and out-of-pocket pricing can be significant without insurance. Always make sure to check current pricing with your pharmacy or provider. 

In some situations, a licensed provider may determine that compounded semaglutide is appropriate for an individual patient. Compounded medications are not FDA-approved, and availability depends on applicable regulatory requirements and clinical appropriateness. 

Whichever route you’re considering, both of these GLP-1 pills require a prescription from a licensed provider. Telehealth may make the evaluation process more accessible for some individuals: you can complete an eligibility assessment and provider consultation entirely online, without navigating in-person scheduling. 

Eden offers provider-guided GLP-1 treatment programs with transparent pricing and free expedited shipping, so you know what you’re paying for from the start. If you’re curious to determine what may be appropriate for you, fill out our brief online intake.